Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

24 oct. 2024 09h59 HE | Source: Research and Markets

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review 2024: Drug Code/INN, Patent/Expiry, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage

Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides...
23 févr. 2024 07h31 HE | Source: Research and Markets

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review 2024

Dublin, Feb. 23, 2024 (GLOBE NEWSWIRE) -- The "Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides...
14 déc. 2023 10h43 HE | Source: Research and Markets

EMPAVELI (Pegcetacoplan) Drug Insight and Market Forecasts, 2019-2022 and 2023-2032

Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "EMPAVELI Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides comprehensive...